CDA | Evidence Driven
CDA | Evidence Driven

Reimbursement Review Reports

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Export to CSV
Brand Name Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Gavreto pralsetinib RET fusion-positive non-small cell lung cancer Reimburse with clinical criteria and/or conditions Complete
Keytruda pembrolizumab Renal cell carcinoma, adjuvant Reimburse with clinical criteria and/or conditions Complete
Jakavi ruxolitinib Graft versus host disease Reimburse with clinical criteria and/or conditions Complete
Enhertu trastuzumab deruxtecan Metastatic HER2 positive breast cancer Reimburse with clinical criteria and/or conditions Complete
Retevmo selpercatinib Thyroid cancer Reimburse with clinical criteria and/or conditions Complete
Palynziq pegvaliase Phenylketonuria Reimburse with clinical criteria and/or conditions Complete
Keytruda and Lenvima pembrolizumab and lenvatinib Advanced endometrial cancer Reimburse with clinical criteria and/or conditions Complete
Keytruda pembrolizumab Triple-negative breast cancer Reimburse with clinical criteria and/or conditions Complete
Poteligeo mogamulizumab mycosis fungoides (MF), Sézary syndrome (SS) Reimburse with clinical criteria and/or conditions Complete
Cibinqo abrocitinib Atopic dermatitis, moderate to severe Reimburse with clinical criteria and/or conditions Complete
Last Updated : May 10, 2024